The preparations for the CBD epilepsy study were started in December 2017, including hiring a full-time research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; we have completed the anticipated enrollment of 60 dogs. Additionally, we have been working with outside clinics in Colorado to help us in the enrollment process of the study. Three local specialty clinics with board-certified neurologists are conducting the study with CSU’s oversight at their hospitals and general veterinarians are helping with the recheck appointments and blood draws. Continue reading “Research Update CHF 02323 Final: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”
Research Update CHF 02252 Final: Investigating a Ketogenic Medium-Chain Triglyceride (MCT) Supplement for the Treatment of Drug-Resistant Canine Idiopathic Epilepsy and Its Behavioral Comorbidities
Canine epilepsy is a chronic neurological condition, often requiring lifelong medication with anti-epileptic drugs (AEDs). Despite appropriate treatment with available AEDs, seizure freedom may not always be achievable. There is an urgent need to develop alternative treatments to improve the quality of life (QoL) of drug-resistant patients, who may continue to experience unpleasant AED side- effects despite their lack of success. Continue reading “Research Update CHF 02252 Final: Investigating a Ketogenic Medium-Chain Triglyceride (MCT) Supplement for the Treatment of Drug-Resistant Canine Idiopathic Epilepsy and Its Behavioral Comorbidities”
Research Update CHF 02323 EY-3: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
The preparations for the CBD epilepsy study were started in December 2017, including hiring a full[1]time research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. Continue reading “Research Update CHF 02323 EY-3: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”
Research Update Mid-year 3 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
The preparations for the CBD epilepsy study were started in December 2018, including hiring a fulltime research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; therefore, we are on track with 54 patients in 2 1/2 years.
Research Update Mid-year 2 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
Research Update from Dr. Stephanie McGrath looking at use of CBD for the treatment of epilepsy.
Research Update Mid-Year-3 CHF-02252: Investigating a Ketogenic Medium-Chain Triglyceride (MCT) Supplement for the Treatment of Drug-Resistant Canine Idiopathic Epilepsy and Its Behavioral Comorbidities
Research Update from Dr. Volk for supplemental treatment of epilepsy.
Research Update Mid-Year 1 for Identification of Genetic Risk Factors for Canine Epilepsy
Research update for Dr. Johnson’s work looking to identify possible genetic risk factors for canine epilepsy.
Research Update Mid-Year 1 for ketogenic MCT supplement therapy use in treating idiopathic canine epilepsy
Update on progress of Dr. Volk’s work looking at the benefits of using a ketogenic MCT supplement to aid in treatment of dogs with idiopathic canine epilepsy.
